Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Anthony Ricci

Allergy East Greenwich, RI Medical Doctor

NPI 1275646440 CMS profile 148324

63 Cedar Ave, Ste 7, East Greenwich, RI 02818

Open in the dashboard

General payments

$9,422

304 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Anthony Ricci of East Greenwich, RI is reported in the CMS Open Payments database as having received $9,422 across 304 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $49 2
2022 General $240 12
2021 General $1,419 82
2020 General $2,134 88
2019 General $5,579 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Ricci
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Anthony Ricci were reported at $0. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Anthony Ricci Allergy median Middle half National median
2019 $5,579 $506 $151–$1,337 $163
2020 $2,134 $409 $108–$1,162 $114
2021 $1,419 $549 $125–$1,485 $132
2022 $240 $666 $161–$1,594 $149
2023 $49 $780 $186–$1,916 $160
2024 $0 $1,031 $271–$2,196 $164
2025 $0 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Pfizer Inc. $4,330 45 payments
  2. GlaxoSmithKline, LLC. $991 66 payments
  3. Regeneron Healthcare Solutions, Inc. $838 32 payments
  4. AstraZeneca Pharmaceuticals LP $747 41 payments
  5. Genzyme Corporation $500 23 payments
  6. Grifols USA, LLC $434 14 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $266 10 payments
  8. CSL Behring $203 10 payments
  9. Novartis Pharmaceuticals Corporation $181 12 payments
  10. Genentech USA, Inc. $117 6 payments
  11. Other $816 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,533 299 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,805 3 payments
  3. Travel and Lodging $84 2 payments
Products named General payments · program years 2019–2023
  1. EUCRISA $4,315 44 payments
  2. DUPIXENT Inflammation And Immunology $838 32 payments
  3. TRELEGY ELLIPTA $594 34 payments
  4. DUPIXENT Immunology $432 19 payments
  5. SPIRIVA RESPIMAT $277 16 payments
  6. NUCALA $266 21 payments
  7. FASENRA Respiratory $234 12 payments
  8. Prolastin-C $230 2 payments
  9. FASENRA Respiratory $210 10 payments
  10. Prolastin-C Liquid $203 12 payments
  11. Other $2,207 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

304 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record